Level Four Advisory Services LLC Has $3.06 Million Stake in Celgene Corporation (CELG)
Level Four Advisory Services LLC increased its stake in Celgene Corporation (NASDAQ:CELG) by 10.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,630 shares of the biopharmaceutical company’s stock after buying an additional 2,256 shares during the period. Level Four Advisory Services LLC’s holdings in Celgene Corporation were worth $3,060,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of CELG. Diversified Trust Co increased its stake in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 9 shares during the last quarter. South Texas Money Management Ltd. increased its stake in shares of Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares during the last quarter. Keel Point LLC increased its stake in shares of Celgene Corporation by 0.9% in the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 28 shares during the last quarter. Quadrant Capital Group LLC increased its stake in shares of Celgene Corporation by 0.8% in the first quarter. Quadrant Capital Group LLC now owns 4,073 shares of the biopharmaceutical company’s stock valued at $492,000 after buying an additional 34 shares during the last quarter. Finally, Steinberg Global Asset Management increased its stake in shares of Celgene Corporation by 0.6% in the first quarter. Steinberg Global Asset Management now owns 6,594 shares of the biopharmaceutical company’s stock valued at $820,000 after buying an additional 39 shares during the last quarter. 78.41% of the stock is owned by institutional investors.
Shares of Celgene Corporation (NASDAQ CELG) traded up 0.18% during mid-day trading on Friday, hitting $130.61. The stock had a trading volume of 2,735,623 shares. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The firm has a 50 day moving average of $134.14 and a 200 day moving average of $124.30. The stock has a market cap of $102.18 billion, a price-to-earnings ratio of 40.45 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the previous year, the business earned $1.44 EPS. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. On average, analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/level-four-advisory-services-llc-has-3-06-million-stake-in-celgene-corporation-celg/1479196.html.
Several equities research analysts have recently weighed in on the company. Jefferies Group LLC set a $154.00 target price on Celgene Corporation and gave the stock a “buy” rating in a research report on Saturday, May 13th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and upped their target price for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Vetr raised Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price for the company in a research report on Thursday. Robert W. Baird reaffirmed an “outperform” rating and issued a $162.00 target price on shares of Celgene Corporation in a research report on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 target price on Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 6th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company. Celgene Corporation presently has a consensus rating of “Buy” and a consensus target price of $147.00.
In other Celgene Corporation news, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the sale, the director now owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of Celgene Corporation stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the sale, the insider now directly owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. Insiders have sold a total of 235,255 shares of company stock valued at $31,377,042 in the last ninety days. Company insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.